Compare · HJLI vs MDLN
HJLI vs MDLN
Side-by-side comparison of Hancock Jaffe Laboratories, Inc. (HJLI) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HJLI and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN carries a market cap of $49.77B.
- MDLN has hit the wire 25 times in the past 4 weeks while HJLI has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 0 for HJLI).
- Company
- Hancock Jaffe Laboratories, Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- -
- $49.77B
- 1M return
- -
- +7.21%
- 1Y return
- -
- -7.15%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2025
- News (4w)
- 0
- 25
- Recent ratings
- 0
- 25
Hancock Jaffe Laboratories, Inc.
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Latest HJLI
- Hancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- enVVeno Medical Corporation Successfully Completes Rebranding
- Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
- Hancock Jaffe Laboratories, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
- SEC Form SC 13G filed by Hancock Jaffe Laboratories, Inc.
- SEC Form 4: Gray Robert converted options into 1,042 units of Common Stock, increasing direct ownership by 19% to 6,614 units
- SEC Form 4: Jenusaitis Matthew converted options into 1,042 units of Common Stock, increasing direct ownership by 22% to 5,884 units
- Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
- SEC Form 8-K filed by Hancock Jaffe Laboratories, Inc.
Latest MDLN
- Large owner Cp Circle Ml Holdco Gp, Llc converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Mozart Coinvestment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- Large owner Tc Group Cayman Investment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Group Inc. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. converted options into 12,128,729 shares and disposed of 12,128,729 units of Class B Common Stock (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- SEC Form 424B4 filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers